UBC Faculty Research and Publications

HIV sero-conversion during late pregnancy : when to retest Kalk, E.; Slogrove, Amy L.; Speert, D. P. (David P.); Bettinger, Julie A.; Cotton, M. F.; Esser, Michael J. (Michael Joachim), 1965- Jun 30, 2013

Your browser doesn't seem to have a PDF viewer, please download the PDF to view this item.

Item Metadata

Download

Media
52383-Kalk_E_et_al_HIV_sero-conversion.pdf [ 217.17kB ]
Metadata
JSON: 52383-1.0228096.json
JSON-LD: 52383-1.0228096-ld.json
RDF/XML (Pretty): 52383-1.0228096-rdf.xml
RDF/JSON: 52383-1.0228096-rdf.json
Turtle: 52383-1.0228096-turtle.txt
N-Triples: 52383-1.0228096-rdf-ntriples.txt
Original Record: 52383-1.0228096-source.json
Full Text
52383-1.0228096-fulltext.txt
Citation
52383-1.0228096.ris

Full Text

ORIGINAL ARTICLEJUNE 2013, Vol. 14, No. 2   SAJHIVMED    90The South African National Prevention of Mother-to-Child Transmission of HIV programme has resulted in significant reductions in vertical transmission, but new infant HIV infections continue to occur. We present two cases of HIV seroconversion during late pregnancy, demonstrating the limitations of the current programme. These could be mitigated by expanding the programme to include maternal testing at delivery and at immunisation clinic visits as we pursue the elimination of mother-to-child transmission.S Afr J HIV Med 2013;14(2):90-92. DOI:10.7196/SAJHIVMED.903CASE REPORTHIV sero-conversion during late pregnancy – when to retestE Kalk,1 MB BCh, PhD, Dip HIV Man; A Slogrove,1,2 MB ChB, FCPaed (SA), MMed; D P Speert,2 MD, FRCP(C);  J A Bettinger,3 PhD, MPH; M F Cotton,1 MB BCh, FCPaed (SA), PhD; M Esser,4 MB BCh, MMedPaed (Rheum)1  Children’s Infectious Diseases Research Unit (KIDCRU), Department of Paediatrics and Child Health, Stellenbosch University, Stellenbosch, South Africa2 Department of Pediatrics, University of British Columbia, Canada3 Vaccine Evaluation Center, British Columbia Children’s Hospital and University of British Columbia, Canada4 National Health Laboratory Service and Department of Pathology (Immunology), Stellenbosch University, Stellenbosch, South AfricaCorresponding author: E Kalk (kalk@sun.ac.za)In order to identify HIV-infected women and offer antiretroviral (ARV) prophylaxis, the South African National Prevention of Mother-To-Child Transmission (PMTCT) of HIV programme recommends 2 HIV tests during pregnancy: at the first antenatal visit and at 32 weeks of gestation.[1] We present two cases that suggest that additional HIV testing strategies are needed to help eliminate the mother-to-child transmission of HIV.In a longitudinal study on HIV-exposed infants, we recruited infants whose mothers were known to be HIV-infected post partum along with a control group of infants born to HIV-negative women. All women delivering at the Kraaifontein Midwife Obstetric Unit were eligible for enrolment. HIV-exposed infants were matched with HIV-unexposed controls within one month of birth. Mother-infant pairs were recruited within three days of delivery and a CD4+ T-cell count was performed on all women regardless of HIV status. In accordance with the study protocol, the infants were reviewed at 2 weeks of age and regularly thereafter. At the 2-week visit, the HIV status of the uninfected mothers was confirmed with an HIV rapid assay using finger-prick blood (Alere Determine HIV 1/2).Recently, HIV infection was identified on the rapid tests at the 2-week visit in 2 women (Table 1). According to antenatal clinic documentation, both tested negative during pregnancy: at booking (at 21 weeks and 28 weeks of gestation, respectively) and at 32 weeks of gestation, as recommended in the national guideline.[1] Neither infant was born before 38 weeks of gestation. The HIV rapid assay in use in the antenatal clinic at the time was the First Response HIV1-2-0 Card Test (Premier Medical Corporation Ltd, India). According to policy, only a single test is required to screen for HIV. Positive screening tests are confirmed with a second rapid assay (ABON HIV 1/2/0 Tri-Line HIV Rapid Test Device).Both women elected to breastfeed, although one mother switched to infant formula after one week owing to poor feeding. Her CD4+ T-cell count at delivery was 680 x 106 cells/l. Her infant was symptomatic at age 2 weeks and was immediately hospitalised, requiring transfer to the intensive care unit. An HIV DNA polymerase chain reaction (PCR) test (Amplicor HIV-1 DNA prototype assay 1.5) at 2 weeks was positive.The CD4+ count of the second woman was 157 x 106 cells/l at delivery. Her baby was well and the HIV DNA PCR at 2 weeks was negative. Daily nevirapine (NVP) for the infant was initiated and the mother was referred for combination antiretroviral therapy (cART) which was commenced within 2 weeks. DiscussionThese two cases raise concerns about antenatal HIV screening and the implications for vertical transmission. As expected, neither woman received any ARV prophylaxis. A recent Medical Research Council (MRC) report on the effectiveness of the national PMTCT programme in South Africa[2] demonstrated that, among mothers who reported being HIV-negative, 4.1% had infants who were HIV-exposed at 4 - 8 weeks (measured by the presence of HIV antibodies in the infants’ blood). A 2007 surveillance study in KwaZulu-Natal (KZN) found that 6.9% of infants whose mothers reported a negative HIV status had similar evidence of exposure (i.e. the CASE  REPORTConsider a regimen withISENTRESSTM in adultHIV-1 infected patients◆  In the BENCHMRK studya, treatment-experienced patients failing ART* with triple-class resistance, ISENTRESSTM + OBT** had durable antiretroviral and immunological ef cacy, sustained through week 1921◆  In the SPIRAL studyb, ISENTRESSTM + ARV backbone therapy demonstratedLifting the  burden of HIVReferences: 1. Eron JJ, Cooper DA, et al; Exploratory analysis in the BENCHMRK studies at week 192: Late outcomes based on early virological responses. Poster Presentation. IAS 2011. Abstract # MOPE225. 2. Martinez E, Larrousse M, Llibre JM, et al; for SPIRAL Study Group. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL raltegravir in the management of HIV-1 infection. AIDS. 2010;24(11):1697-1707. 3. Okeke NL, Hicks C. Role of raltegravir in the management of HIV-1 infection. HIV/AIDS – Research and Palliative Care. 2011;3:81-92. 4. Steigbigel RT, Cooper DA, Kumar PN, et al; for BENCKMRK Study Teams. Raltegravir both optomized back-ground therapy for resistant HIV-1 infection. N Engl J Med. 2008; 359(4):339-354.ISENTRESS  S4  Each  lm-coated tablet contains 400 mg of raltegravir. Reg. No.: 42/20.2.8/0687.◆  Less effects on lipids◆  Similar ef cacycompared with ritonavir-boosted PIs + backbone therapy2◆  ISENTRESSTM does not inhibit or induce cytochrome P450 and has a low propensity for drug-drug interactions3 “ISENTRESSTM has a generally favourable safety pro leand its potencyc in suppression of HIV-1 replication willlikely ensure its place in the range of successful HIV-1antiretroviral treatment options for years to come”3SELECTED SAFETY INFORMATIONISENTRESSTM is indicated in combination with other antiretroviral medicinal products for the treatment of HIV-1infection in treatment-experienced adult patients with evidence of HIV-1 replication despite ongoing antiretroviral therapy. The dosage of ISENTRESSTM is 400 mg administered orally, twice daily, with or without food. ISENTRESSTM is contra-indicated in patients who are hypersensitive to any component of this medicine. During the initial phase of treatment, patients responding to antiretroviral therapy may develop an in ammatory response to indolent or residual opportunistic infections (such as Mycobacterium avium complex, cytomegalovirus, Pneumocystis jiroveci pneumonia and tuberculosis or reactivation of varicella zoster virus), which may necessitate further evaluation and treatment. Caution should be used when co-administering ISENTRESSTM with strong inducers of uridine diphosphate glucoronosyl-transferase (UGT) 1A1 (eg, rifampin) due to reduced plasma concentrations of ISENTRESSTM. ISENTRESSTM is not recommended for use in pregnancy. Breastfeeding is not recommended while taking ISENTRESSTM. In addition, it is recommended that HIV-infected mothers not breastfeed their infants to avoid risking postnatal transmission of HIV. The safety pro le and effectiveness of ISENTRESSTM in paediatric patients less than 16 years of age have not been established. The use of other active agents with ISENTRESSTM is associated with a greater likelihood of treatment response.Before prescribing, please consult the full package insert. * ART = antiretroviral therapy ** OBT = optimised background therapy (OBT was selected by the investigator based on baseline genotypic/phenotypic resistance testing and prior ART history)a Two multicentre, randomised, double-blind, placebo-controlled studies in patients with triple-class-resistant virus who received either ISENTRESSTM 400mg BID + OBT** (n = 462) or placebo + OBT** (n = 237) to evaluate the safety and   ef cacy of ISENTRESSTM + OBT** versus OBT** alone. Primary end point was the proportion of patients who achieved HIV-1 RNA levels <400 copies/ml after 16 weeks.4b 48-week multicentre, open-label trial in which HIV-infected adults with <50 copies/ml of plasma HIV RNA were randomised (1:1) to switch from ritonavir-boosted protease inhibitor to raltegravir or to continue on ritonavir-boosted protease   inhibitor-based therapy. Primary end point was the proportion of patients free of treatment failure at 48 weeks. Secondary end point was to evaluate whether switching from a ritonavir-boosted protease inhibitor component to raltegravir   would result in a better lipid pro le and similar ef cacy at Week 48.2c In the BENCHMRK study, patients on ISENTRESSTM + OBT** achieved HIV-1 RNA levels <50 copies/ml at week 48 in 62.1 % of patients, compared with 32.9 % of patients on OBT** alone (p<0.001).4Copyright © 2012 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Whitehouse Station, NJ, U.S.A.  All rights reserved.MSD (Pty) Ltd (Reg. No. 1996/003791/07), Private Bag 3, Halfway House 1685INFC-1035392-0001 08/1391    SAJHIVMED   JUNE 2013, Vol. 14, No. 2CASE  REPORTpresence of HIV antibodies in the infants’ blood).[3] Of concern is that the vertical transmission rate in this group was high (31% v. an overall rate of 20.2% at that time).It is possible that some women knew, but did not admit their HIV-positive status. However, the KZN study was anonymous, and the MRC report demonstrated a high uptake of HIV testing and disclosure, making it unlikely that this scenario contributed significantly to the observations.[2,3] Moreover, the two subjects described here each had HIV-negative results for rapid tests on two different occasions.Alternatively, there may have been a problem with the HIV rapid antibody assay, including that the tests were conducted within the window period. Antibodies to HIV can be detected at 2 - 3 weeks after infection by fourth-generation laboratory enzyme-linked immunosorbent assay (ELISA) tests, which detect both antibody to HIV and p24Ag (Fiebig stage II and III). [4] The third-generation rapid tests have a window period of three to four weeks post infection (Fiebig stage III).[4,5] Testing during this time will yield a false-negative result. The reported sensitivity and specificity of the First Response HIV 1-2-0 Card Test are 100% and 98.8% when used correctly[5] within the WHO recommended range of >98%.[6] In our subjects, this explanation could only apply to the second assay at 32 weeks, and would indicate recent acquisition of infection. The rapid assay may have recorded a false-negative result for the second test. All batches of rapid tests are validated by the National Institute for Communicable Diseases (NICD) on a panel of laboratory samples, but they have not been validated in pregnant women specifically or in the field. Assay sensitivities have been reported between 87% to 95% in clinics depending on the product.[2,7] More data are therefore required to assess and validate HIV rapid assays in pregnant women, and to ensure the quality of testing at clinic level. Importantly, there is no quality-control procedure for negative rapid tests.The most likely explanation for our findings is true acquisition of HIV during pregnancy and breastfeeding. Pregnancy poses an increased risk for HIV acquisition by women, even after adjustment for behavioural and other factors; it is possible that the hormonal and other biological changes associated with pregnancy play a role.[8] High viral loads during primary HIV infection increase the risk of vertical transmission in utero, peri partum and post partum,[9,10] especially in the absence of ARV prophylaxis. In studies in Botswana and SA, new mothers with negative HIV test results or of unknown HIV status were tested immediately post partum or at infant immunisation visits. The results demonstrated a seroconversion rate of 2.4 - 7.9% during pregnancy and post partum. [2,7,11,12] These women are at high risk of vertical transmission.[13-15] In addition, they are more likely to use mixed feeding practices, placing their infants at greater risk for HIV infection. [2,16-18] ‘Mixed feeding’ refers to the use of breast milk in addition to other fluids (infant formula, water, tea) for infant feeding. The increased incidence of mixed feeding observed in these women is presumably because, having tested HIV-negative, they perceive no risk.Repeat HIV testing of mothers during late pregnancy, at delivery or at the clinic immunisation visits, would identify women who acquire HIV during pregnancy and in the early post-partum period. The HIV diagnosis of infants whose mothers tested negative during pregnancy is often delayed,[18] with significant implications for morbidity and mortality.[19] Most SA women deliver at a healthcare facility[20] and 99% attend the 6-week vaccination visit.[2] Moreover, testing at these time-points shows high uptake,[11,21,22] while offering HIV tests to both partners may identify discordant couples and allow counselling on HIV prevention.[2] A proviso to this is increasing evidence that, even within discordant partnerships, a significant number of new HIV infections arise from extra-couple transmission.[23]ConclusionWhile the elimination of mother-to-child transmission of HIV is feasible, it will require a modification of current protocols/guidelines to include repeat HIV testing of women at delivery and/or post partum, a quality-control strategy for laboratory testing of a small percentage of negative rapid tests, involvement of male partners in testing and counselling, and an emphasis on exclusive feeding practices, regardless of HIV status.Ethics approval. The Mother Infant Health Study (MIHS) is approved by the Ethics Committees of Stellenbosch University and the University of British Columbia.Conflict of interest. None.Funding acknowledgement. The MIHS is supported by the Peter Wall Institute of Advanced Studies, University of British Columbia. AS receives funding from the Canadian Institute of Health Research Canada-HOPE.Acknowledgements. The authors thank the ever-motivated MIHS team at KID-CRU and Kraaifontein MOU in Cape Town; and Tobias Kollmann, Arlene Kallos and Kim Marty from the team in Vancouver.References1. National Department of Health, South African National AIDS Council. Clinical Guidelines: Prevention of Mother-to-Child Transmission. Pretoria: National Department of Health, 2010. 2. Goga AE, Jackson DJ. Evaluation of the Effectiveness of the National Prevention of Mother-to-Child Transmission (PMTCT) Programme Measured at Six Weeks Postpartum in South Africa, 2010: Medical Research Council of South Africa, National Department of Health, PEPFAR/US Centers for Disease Control and Prevention, 2012.3. Rollins N, Little K, Mzolo S, et al. Surveillance of mother-to-child transmission prevention programmes at immunization clinics: The case for universal screening. AIDS 2007;21:1341-1347. [http://dx.doi.org/10.1097/QAD.0b013e32814db7d4]4. Evian C. Primary HIV Care. 5th ed. Cape Town: Jacana, 2011:45-62.5. World Health Organization Department of Essential Health Technologies. HIV Assays: Operational Table 1. Patient characteristicsPatientMaternal age (years)Gestational age, first ANC (weeks)Gestational age, first HIV test (weeks)Gestational age, second HIV test (weeks)Infant date of birth Maternal CD4+ count at birth (x106cells/l)Feeding choiceInfant PCR test at 2 weeks1 29 21 21 32 31/10/2012 680 Breast Positive2 23 28 28 32 05/11/2012 157 Breast NegativeANC = antenatal clinic visit; PCR = polymerase chain reaction.JUNE 2013, Vol. 14, No. 2   SAJHIVMED     92CASE  REPORTCharacteristics Report 14. Geneva: WHO, 2004. http://www.who.int/eht/ (accessed 1 April 2013).6. World Health Organization. Guidelines for HIV Diagnosis and Monitoring of Antiretroviral Therapy: Revised version 2009. Geneva, Switzerland: World Health Organization; 2009. http://www.who.int/hiv/pub/guidelines/en/ (accessed 1 April  2013).7. Bhowan K, Kalk E, Khan S, et al. Identifying HIV infection in women: how does a fourth generation rapid test perform? African Journal of Laboratory Medicine 2011;1(1). [http://dx.doi.org/10.4102/ajlm.v1i1.4]8. Gray RH, Li X, Kigozi G, et al. Increased risk of incident HIV during pregnancy in Rakai, Uganda: A prospective study. Lancet 2005;366:1182-1188. [http://dx.doi.org/10.1016/S0140-6736(05)67481-8]9. Liang K, Gui X, Zhang YZ, et al. A case series of 104 women infected with HIV-1 via blood transfusion postnatally: High rate of HIV-1 transmission to infants through breast-feeding. J Infect Dis 2009;200:682-686. [http://dx.doi.org/10.1086/605123]10. Magder LS, Mofenson L, Paul ME, et al. Risk factors for in utero and intrapartum transmission of HIV. J Acquir Immune Defic Syndr 2005;38:87-95. [http://dx.doi.org/10.1097/00126334-200501010-00016] 11. Moodley D, Esterhuizen T, Reddy L, et al. Incident HIV infection in pregnant and lactating women and its effect on mother-to-child transmission in South Africa. J Infect Dis 2011;203:1231-1234. [http://dx.doi.org/10.1093/infdis/jir017] 12. Technau K. Can a routine peri-partum HIV counselling and testing service for women improve access to HIV prevention, early testing and treatment of children? http://wiredspace.wits.ac.za/handle/10539/8054 (accessed 1 April 2013).13. Bulterys M, Ellington S, Kourtis AP. HIV-1 and breastfeeding: Biology of transmission and advances in prevention. Clin Perinatol 2010;37:807-824. [http://dx.doi.org/10.1016/j.clp.2010.08.001] 14. Humphrey JH, Marinda E, Mutasa K, et al. Mother to child transmission of HIV among Zimbabwean women who seroconverted postnatally: Prospective cohort study. BMJ 2010;341:c6580. [http://dx.doi.org/10.1136/bmj.c6580] 15. Johnson LF, Stinson K, Newell ML, et al. The contribution of maternal HIV seroconversion during late pregnancy and breastfeeding to mother-to-child transmission of HIV. J Acquir Immune Defic Syndr 2011;31:474-480. [http://dx.doi.org/10.1097/QAI.0b013e3182432f27]16. Horvath T, Madi B, Iuppa I, et al. Interventions for preventing late postnatal mother-to-child transmission of HIV. Cochrane Database of Systematic Reviews 2009(1):CD006734. [http://dx.doi.org/10.1002/14651858.CD006734.pub2]17. Iliff PJ, Piwoz EG, Tavengwa NV, et al. Early exclusive breastfeeding reduces the risk of postnatal HIV-1 transmission and increases HIV-free survival. AIDS 2005;19:699-708. [http://dx.doi.org/10.1097/01.aids.0000166093.16446.c9]18. Kalk E, Zunza M, Cotton MF. Abstract P80: Reasons for Failure of Vertical Transmission Prevention in the Western Cape, South Africa – a Retrospective Descriptive Study. First Southern African HIV Clinicians Society Conference, Cape Town, South Africa, November 2012.19. Violari A, Cotton MF, Gibb DM, et al. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med 2008;359:2233-2244. [http://dx.doi.org/10.1056/NEJMoa0800971] 20. Myer L, Harrison A. Why do women seek antenatal care late? Perspectives from rural South Africa. J Midwifery Womens Health 2003;48:268-272. [http://dx.doi.org/10.1016/S1526-9523(02)00421-X] 21. Lu L, Legwaila K, Motswere C, et al. HIV incidence in pregnancy and the first post-partum year and implications for PMTCT programs, Francistown, Botswana, 2008. 16th Conference on Retroviruses and Opportunistic Infections, Montreal, Canada, 2009.22. Lu L, Motswere-Chirwa C, Legwaila K, et al. Abstract 15: HIV incidence in women during the first postpartum year: Implications for PMTCT programs, Francistown, Botswana, 2010. Third International Workshop on HIV Pediatrics. Rome, Italy.23. Bellan SE, Fiorella KJ, Melesse DY, et al. Extra-couple HIV transmission in sub-Saharan Africa: A mathematical modelling study of survey data. Lancet. 2013 (in press). [http://dx.doi.org/10.1016/S0140-6736(12)61960-6] 

Cite

Citation Scheme:

        

Citations by CSL (citeproc-js)

Usage Statistics

Share

Embed

Customize your widget with the following options, then copy and paste the code below into the HTML of your page to embed this item in your website.
                        
                            <div id="ubcOpenCollectionsWidgetDisplay">
                            <script id="ubcOpenCollectionsWidget"
                            src="{[{embed.src}]}"
                            data-item="{[{embed.item}]}"
                            data-collection="{[{embed.collection}]}"
                            data-metadata="{[{embed.showMetadata}]}"
                            data-width="{[{embed.width}]}"
                            async >
                            </script>
                            </div>
                        
                    
IIIF logo Our image viewer uses the IIIF 2.0 standard. To load this item in other compatible viewers, use this url:
http://iiif.library.ubc.ca/presentation/dsp.52383.1-0228096/manifest

Comment

Related Items